Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Barclays 28th Annual Global Healthcare Conference (March 2026)
7 slides from Zealand Pharma A/s's conference presentation, Mar 11, 2026
Slide 1: Zealand Pharma: Transforming the future of metabolic health
Zealand Pharma Transforming the future of metabolic health Barclays 28th Annual Global Healthcare Conference March 11, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Zealand Pharma is transforming the future of metabolic health
Zealand Pharma is transforming the future of metabolic health Redefining the near-term future Building the world’s most valuable of weight management metabolic health pipeline +10 clinical Differentiated programs by 2030 Leading programs obesity pipeline Our unfair and Solid cash backed by strong wi
Slide 4: Real world data reveal a major gap in current obesity care
Real world data reveal a major gap in current obesity care Low treatment penetration Obesity needs new drug classes Desired weight loss contradicts ~3-5% of eligible patients in the 1 class available today vs. +8 Weight loss Olympics U.S. on pharmacotherapy1 classes for other chronic diseases 1 in 5
Slide 5: Petrelintide has potential to redefine the weight management experience
Petrelintide has potential to redefine the weight management experience • Potential foundational, first choice treatment option setting a new standard for what to expect from a weight loss journey • Phase 2 ZUPREME-1 trial: Double-digit weight reduction with placebo-like tolerability • Petrelintide/
Slide 6: Boehringer Ingelheim positioned as next obesity market entrant with survodutide
Boehringer Ingelheim positioned as next obesity market entrant with survodutide “See Obesity, Think Liver” People who are overweight or have obesity ~15–30%2,3 T2D MASLD ~75%1 ~10–15%4 MASH ~34%1 CVD CKD ~20%5,6 Boehringer Ingelheim at ObesityWeek 2025 Survodutide is licensed to Boehringer Ingelheim
Slide 7: 2026: Most defining and catalyst-rich year yet
2026: Most defining and catalyst-rich year yet NON-EXHAUSTIVE Petrelintidea Survodutideb Building the pipeline (amylin analog) (GCGR/GLP-1R) of the future ✓ Results from Ph2 ZUPREME-1 Results from Ph3 obesity ZP9830 (Kv1.3) program Results from Ph1a SAD and MAD, and clinical advancement Results from
Zealand Pharma — Barclays 28th Annual Global Healthcare Conference (March 2026) on 6ix